249 related articles for article (PubMed ID: 29111815)
1. Novel treatment regimen of Vogt-Koyanagi-Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents.
Yang P; Ye Z; Du L; Zhou Q; Qi J; Liang L; Wu L; Wang C; Kijlstra A
Curr Eye Res; 2018 Feb; 43(2):254-261. PubMed ID: 29111815
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.
Abu El-Asrar AM; Al Tamimi M; Hemachandran S; Al-Mezaine HS; Al-Muammar A; Kangave D
Acta Ophthalmol; 2013 Sep; 91(6):e486-93. PubMed ID: 23575246
[TBL] [Abstract][Full Text] [Related]
3. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
[TBL] [Abstract][Full Text] [Related]
4. Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease.
Concha-Del Río LE; Gómez L; Arellanes-García L
Arch Soc Esp Oftalmol (Engl Ed); 2018 May; 93(5):225-230. PubMed ID: 29258782
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
Nakayama M; Keino H; Watanabe T; Okada AA
Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
[TBL] [Abstract][Full Text] [Related]
8. Vogt-Koyanagi-Harada disease presenting as acute angle closure glaucoma at onset.
Yang P; Liu X; Zhou H; Guo W; Zhou C; Kijlstra A
Clin Exp Ophthalmol; 2011; 39(7):639-47. PubMed ID: 22452682
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.
Feng H; Chen W; Yang J; Kong H; Li H; He Y; Wang H
BMC Ophthalmol; 2024 Jun; 24(1):238. PubMed ID: 38849758
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease.
Cuchacovich M; Solanes F; Díaz G; Cermenati T; Avila S; Verdaguer J; Verdaguer JI; Carpentier C; Stopel J; Rojas B; Traipe L; Gallardo P; Sabugo F; Zanoli M; Merino G; Villarroel F
Ocul Immunol Inflamm; 2010 Jun; 18(3):200-7. PubMed ID: 20482399
[TBL] [Abstract][Full Text] [Related]
11. Vogt-Koyanagi-Harada syndrome in children: report of a case and review of the literature.
Berker N; Ozdamar Y; Soykan E; Ozdal P; Ozkan SS
Ocul Immunol Inflamm; 2007; 15(4):351-7. PubMed ID: 17763135
[TBL] [Abstract][Full Text] [Related]
12. [Recurrent uveitis with bilateral exudative retinal detachment. 10-year-old boy with bilaterally impaired vision and eye pain. Vogt-Koyanagi-Harada syndrome].
Kohnen EM; Pansdorf Y; Zubcov A
Ophthalmologe; 2004 Apr; 101(4):390-3. PubMed ID: 15067421
[No Abstract] [Full Text] [Related]
13. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients.
Yang P; Ren Y; Li B; Fang W; Meng Q; Kijlstra A
Ophthalmology; 2007 Mar; 114(3):606-14. PubMed ID: 17123618
[TBL] [Abstract][Full Text] [Related]
14. Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease.
Urzua CA; Velasquez V; Sabat P; Berger O; Ramirez S; Goecke A; Vásquez DH; Gatica H; Guerrero J
Acta Ophthalmol; 2015 Sep; 93(6):e475-80. PubMed ID: 25565265
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy.
Takayama K; Obata H; Takeuchi M
Ocul Immunol Inflamm; 2020 Apr; 28(3):509-512. PubMed ID: 31268769
[No Abstract] [Full Text] [Related]
16. Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.
Arevalo JF; Lasave AF; Gupta V; Kozak I; Al Harbi MB; Al Rushood AA; Al Dhibi HA
Ocul Immunol Inflamm; 2016 Oct; 24(5):521-9. PubMed ID: 26399962
[TBL] [Abstract][Full Text] [Related]
17. High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids.
Sakata VM; da Silva FT; Hirata CE; Marin ML; Rodrigues H; Kalil J; Costa RA; Yamamoto JH
Graefes Arch Clin Exp Ophthalmol; 2015 May; 253(5):785-90. PubMed ID: 25592477
[TBL] [Abstract][Full Text] [Related]
18. A case of probable Vogt-Koyanagi-Harada disease in a 3-year-old girl.
Katsuyama A; Kusuhara S; Awano H; Nagase H; Matsumiya W; Nakamura M
BMC Ophthalmol; 2019 Aug; 19(1):179. PubMed ID: 31409322
[TBL] [Abstract][Full Text] [Related]
19. Vogt-Koyanagi-Harada Syndrome in a Group of Patients in Two Ophthalmology Referral Centers in Bogotá, Colombia.
Guayacán CL; Galindo-Mendez B; de-la-Torre A
Ocul Immunol Inflamm; 2018; 26(7):1123-1127. PubMed ID: 28910557
[TBL] [Abstract][Full Text] [Related]
20. Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up.
Herbort CP; Mantovani A; Bouchenaki N
Int Ophthalmol; 2007; 27(2-3):173-82. PubMed ID: 17457515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
